Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas

被引：45

作者：

Burrows, JN ^{[1
]}

Cumming, JG ^{[1
]}

Fillery, SM ^{[1
]}

Hamlin, GA ^{[1
]}

Hudson, JA ^{[1
]}

Jackson, RJ ^{[1
]}

McLaughlin, S ^{[1
]}

Shaw, JS ^{[1
]}

机构：

[1] AstraZeneca, Resp & Inflammat Res Area, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 01期

关键词：

CCR5; chemokine receptor modulators;

D O I：

10.1016/j.bmcl.2004.10.044

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Investigation of weak screening hits led to the identification of N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-2-phenylacetamides and N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-N'-benzylureas as potent, selective ligands for the human CCR5 chemokine receptor. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：25 / 28

页数：4

共 10 条

[1] Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis:: Lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine [J].

Andres, PG ;

Beck, PL ;

Mizoguchi, E ;

Mizoguchi, A ;

Bhan, AK ;

Dawson, T ;

Kuziel, WA ;

Maeda, N ;

MacDermott, RP ;

Podolsky, DK ;

Reinecker, HC .

JOURNAL OF IMMUNOLOGY, 2000, 164 (12) :6303-6312

[2]

BURROWS J, 2001, Patent No. 01087839

[3] CC chemokine receptor 5 and renal-transplant survival [J].

Fischereder, M ;

Luckow, B ;

Hocher, B ;

Wüthrich, RP ;

Rothenpieler, U ;

Schneeberger, H ;

Panzer, U ;

Stahl, RAK ;

Hauser, IA ;

Budde, K ;

Neumayer, HH ;

Krämer, BK ;

Land, W ;

Schlöndorff, D .

LANCET, 2001, 357 (9270) :1758-1761

[4] Unraveling the chemistry of chemokine receptor ligands [J].

Gao, ZL ;

Metz, WA .

CHEMICAL REVIEWS, 2003, 103 (09) :3733-3752

[5] An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells [J].

Jamil, H ;

Gordon, DA ;

Eustice, DC ;

Brooks, CM ;

Dickson, JK ;

Chen, Y ;

Ricci, B ;

Chu, CH ;

Harrity, TW ;

Ciosek, CP ;

Biller, SA ;

Gregg, RE ;

Wetterau, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11991-11995

[6] Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors [J].

Kazmierski, W ;

Bifulco, N ;

Yang, HB ;

Boone, L ;

DeAnda, F ;

Watson, C ;

Kenakin, T .

BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (13) :2663-2676

[7] Chemokines, chemokine receptors and small-molecule antagonists: recent developments [J].

Onuffer, JJ ;

Horuk, R .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (10) :459-467

[8] Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist [J].

Palani, A ;

Shapiro, S ;

Clader, JW ;

Greenlee, WJ ;

Blythin, D ;

Cox, K ;

Wagner, NE ;

Strizki, J ;

Baroudy, BM ;

Dan, NY .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) :705-708

[9]

PIPITONE N, 2000, CURR OPIN ANTIINFLAM, V2, P9

[10] CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis [J].

Sellebjerg, F ;

Madsen, HO ;

Jensen, CV ;

Jensen, J ;

Garred, P .

JOURNAL OF NEUROIMMUNOLOGY, 2000, 102 (01) :98-106

← 1 →